Treat and Repair Strategy in Patients With Atrial Septal Defect and Significant Pulmonary Arterial Hypertension
Treat and Repair Strategy in Patients With Atrial Septal Defect and Significant Pulmonary Arterial Hypertension
复制标题
DOI：
10.1253/circj.cj-15-0599
复制
发表时间：
2015-12-01
影响因子：
3.3
通讯作者：
Ito, Hiroshi
中科院分区：
文献类型：
--
作者：
Kijima, Yasufumi;Akagi, Teiji;Ito, Hiroshi
背景：房间隔缺损（ASD）和显着肺动脉高压（PAH）患者的治疗策略仍存在争议。本研究旨在评估 PAH 特异性药物和随后的经导管分流管封堵（即治疗和修复策略）对这些患者的效果。 方法和结果：在 646 名 ASD 患者中，22 名患有 PAH 的患者（平均年龄 56 +/- 20 岁）[平均肺动脉压 >= 25 mmHg 且肺血管阻力 (PVR) >= 3 Wood 单位]接受了成功的手术 经导管 ASD 封堵术。手术前，8 名患者接受了 PAH 特异性药物（PHM 组），14 名患者没有接受 PAH 特异性药物（非 PHM 组）。最初，PHM 组与非 PHM 组相比具有更高的 PVR（9.6 +/- 3.8 vs. 4.2 +/- 1.0 木材单位，P
Background: A therapeutic strategy in patients with atrial septal defect (ASD) and significant pulmonary arterial hypertension (PAH) remains controversial. This study aimed to assess the effect of PAH-specific medications and subsequent transcatheter shunt closure (ie, a treat and repair strategy) in these patients.Methods and Results: Among 646 patients with ASD, 22 patients (mean age of 56 +/- 20 years) who had PAH [mean pulmonary artery pressure >= 25 mmHg and pulmonary vascular resistance (PVR) >= 3 Wood units] underwent successful transcatheter ASD closure. Prior to the procedure, 8 patients received PAH-specific medications (PHM group) and 14 patients did not (non-PHM group). Initially, the PHM group had higher PVR compared with non-PHM group (9.6 +/- 3.8 vs. 4.2 +/- 1.0 Wood units, P